menu

Targeting the Fc Receptor Pathway to Treat Red Blood Cell Alloimmunization

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Targeting the Fc Receptor Pathway to Treat Red Blood Cell Alloimmunization

0.25 credits
15 minutes
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.25 credits
Completing the pre-test is required to view this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    Program Chairman:
    Roberto Romero, MD, DMedSci
    Chief, Perinatology Research Branch
    Division of Maternal-Fetal Medicine and Obstetrics
    Division of Intramural Research
    NICHD/NIH/DHHS
    Editor-in-Chief for Obstetrics
    The American Journal of Obstetrics and Gynecology

    How well do you understand the biology of hemolytic disease of the fetus and newborn (HDFN)? What about its connection to the FcRn receptor pathway and IgG? Drs. Lee Shulman and Ken Moise go beyond the basics taught in medical school immunology and look more closely at FcRn’s role in protecting IgG. With an improved understanding of these mechanisms, we can expand therapeutic targets beyond the fetus and newborn and finally put the needles away.  

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Lee P. Shulman, MD, FACOG, FACMG
    The Anna Ross Lapham Professor and Chief
    Division of Clinical Genetics
    Feinberg School of Medicine of Northwestern University
    Chicago, IL

    Consulting Fees: Agile, Aspira, Bayer, Biogix, Celula China, Daiichi Sankyo, Mayne, Organon, Shield
    Other: Astellas (DSMB Chair)

    Faculty:
    Kenneth J. Moise, Jr, MD
    Professor, Department of Women's Health
    Director, Comprehensive Fetal Care Center
    Dell Medical School, University of Texas at Austin
    Austin, TX

    Consulting Fees: BillionToOne, Inc., Health Management Associates, Inc.
    Royalty: UpToDate, Inc.
    Research: Janssen Pharmaceuticals, Inc.

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has nothing to disclose.
    • Kate Nagele has nothing to disclose.
    • Estelle Perera has nothing to disclose.
    • Roberto Romero, MD, has nothing to disclose.
    • Jay Runyon has nothing to disclose.
    • Robert Schneider, MSW, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Explain the pathophysiology underlying fetal/newborn alloimmune disorders, with a focus on hemolytic disease of the fetus and newborn (HDFN)
    • Explain the role of the neonatal Fc receptor pathway, its potential role in HDFN, and how it might be a therapeutic target in the management of HDFN
  • Target Audience

    This activity is designed to meet the educational needs of maternal-fetal medicine physicians, obstetrician-gynecologists, nurse practitioners, and physician assistants.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for .25 AAPA Category 1 CME credits. Approval is valid until October 27, 2023. PAs should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Omnia Education is the leading provider of education for women’s health professionals. Our activities are recognized nationwide for providing credible, relevant, and practical information on issues impacting the female patient. Additionally, our unique focus has transformed the CME learning environment, and our ability to help learners recognize and overcome barriers to optimal performance and optimal patient outcomes has positioned us as a leader in women’s health education.

  • Commercial Support

    This activity is supported by an independent educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Omnia Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Omnia Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Program Chairman:
    Roberto Romero, MD, DMedSci
    Chief, Perinatology Research Branch
    Division of Maternal-Fetal Medicine and Obstetrics
    Division of Intramural Research
    NICHD/NIH/DHHS
    Editor-in-Chief for Obstetrics
    The American Journal of Obstetrics and Gynecology

    How well do you understand the biology of hemolytic disease of the fetus and newborn (HDFN)? What about its connection to the FcRn receptor pathway and IgG? Drs. Lee Shulman and Ken Moise go beyond the basics taught in medical school immunology and look more closely at FcRn’s role in protecting IgG. With an improved understanding of these mechanisms, we can expand therapeutic targets beyond the fetus and newborn and finally put the needles away.  

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Lee P. Shulman, MD, FACOG, FACMG
    The Anna Ross Lapham Professor and Chief
    Division of Clinical Genetics
    Feinberg School of Medicine of Northwestern University
    Chicago, IL

    Consulting Fees: Agile, Aspira, Bayer, Biogix, Celula China, Daiichi Sankyo, Mayne, Organon, Shield
    Other: Astellas (DSMB Chair)

    Faculty:
    Kenneth J. Moise, Jr, MD
    Professor, Department of Women's Health
    Director, Comprehensive Fetal Care Center
    Dell Medical School, University of Texas at Austin
    Austin, TX

    Consulting Fees: BillionToOne, Inc., Health Management Associates, Inc.
    Royalty: UpToDate, Inc.
    Research: Janssen Pharmaceuticals, Inc.

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has nothing to disclose.
    • Kate Nagele has nothing to disclose.
    • Estelle Perera has nothing to disclose.
    • Roberto Romero, MD, has nothing to disclose.
    • Jay Runyon has nothing to disclose.
    • Robert Schneider, MSW, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Explain the pathophysiology underlying fetal/newborn alloimmune disorders, with a focus on hemolytic disease of the fetus and newborn (HDFN)
    • Explain the role of the neonatal Fc receptor pathway, its potential role in HDFN, and how it might be a therapeutic target in the management of HDFN
  • Target Audience

    This activity is designed to meet the educational needs of maternal-fetal medicine physicians, obstetrician-gynecologists, nurse practitioners, and physician assistants.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for .25 AAPA Category 1 CME credits. Approval is valid until October 27, 2023. PAs should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Omnia Education is the leading provider of education for women’s health professionals. Our activities are recognized nationwide for providing credible, relevant, and practical information on issues impacting the female patient. Additionally, our unique focus has transformed the CME learning environment, and our ability to help learners recognize and overcome barriers to optimal performance and optimal patient outcomes has positioned us as a leader in women’s health education.

  • Commercial Support

    This activity is supported by an independent educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Omnia Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Omnia Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule29 Nov 2022